Effects of Intrathecal Dexmedetomidine as an Adjuvant to Low Dose Hyperbaric 0.5% Bupivacaine

• Status: Completed
• Trial end date: 2022-02-18
• Target enrollment: 0
• Participant gender: Male

Summary

Patients will be enrolled in one of the two groups using a computer-generated random number table: Group I will receive 1.5 ml of 0.5% hyperbaric bupivacaine (7.5 mg). Group II will receive 1.2 mL of 0.5% hyperbaric bupivacaine (6 mg) along with 0.3 mL (3 μg )of dexmedetomidine (total 1.5 mL).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sindh Institute of Urology and Transplantation
• Treatments: Bupivacaine; Dexmedetomidine

Criteria

Inclusion Criteria:

• ASA I to ASA II

• Age 50 to 80 years old

• Height between 155cm and 175 cm

Exclusion Criteria:

• History of spine surgery or the presence of an infectious focus on the back

• Patient's refusal to undergo a spinal anaesthesia

• Hypersensitivity to bupivacaine or dexmedetomidine

• Patients taking drugs of abuse or narcotic analgesics

• Diabetic neuropathy

• History of bleeding disorders

• Oral/intravenous anticoagulant therapy

• History of arrhythmias or labile hypertension

• Unco-operative patients

• Hearing defect

• ASA III and IV

• Central or peripheral nervous system disorders

• Severe hypovolemia